articleNature MedicineJan 14, 2022HYBRID OA

Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

NANick AndrewsJSJulia StoweFKFreja KirsebomSTSamuel ToffaRSRuchira Sachdeva

London School of Hygiene & Tropical Medicine · UK Health Security Agency · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in England starting on 14 September 2021. We used a test-negative case-control design to estimate the relative effectiveness of a booster dose of BNT162b2 (Pfizer-BioNTech) compared to only a two-dose primary course (at least 175 days after the second dose) or unvaccinated individuals from 13 September 2021 to 5 December 2021, when Delta variant was dominant in circulation. Outcomes were symptomatic coronavirus disease 2019 (COVID-19) and hospitalization. The relative effectiveness against symptomatic disease 14-34 days after a BNT162b2 or mRNA-1273 (Moderna) booster after a ChAdOx1-S (AstraZeneca) and BNT162b2 as a primary…

Citation impact

378
total citations
FWCI
37.30
Percentile
100%
References
21
Citations per year

Authors

8
  • NA
    Nick AndrewsCorresponding

    London School of Hygiene & Tropical Medicine, UK Health Security Agency

  • JS
    Julia Stowe

    London School of Hygiene & Tropical Medicine, UK Health Security Agency

  • FK
    Freja Kirsebom

    UK Health Security Agency

  • ST
    Samuel Toffa

    UK Health Security Agency

  • RS
    Ruchira Sachdeva

    UK Health Security Agency

Topics & keywords

Topics
Keywords
  • Booster (rocketry)
  • Booster dose
  • Vaccination
  • Disease
  • Coronavirus disease 2019 (COVID-19)
  • Primary care
  • Primary prevention
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
No related works found for this paper.